miR-34a confers chemosensitivity through modulation of MAGE-A and p53 in medulloblastoma.

Recent studies have established miR-34a as a key effector of the p53 signaling pathway and have implicated its role in multiple cancer types. Here, we establish that miR-34a induces apoptosis, G2 arrest, and senescence in medulloblastoma and renders these cells more sensitive to chemotherapeutic agents. These effects are mediated in part by the direct post-transcriptional repression of the oncogenic MAGE-A gene family. We demonstrate that miR-34a directly targets the 3' untranslated regions of MAGE-A genes and decreases MAGE-A protein levels. This decrease in MAGE-A results in a concomitant increase in p53 and its associated transcriptional targets, p21/WAF1/CIP1 and, importantly, miR-34a. This establishes a positive feedback mechanism where miR-34a is not only induced by p53 but increases p53 mRNA and protein levels through the modulation of MAGE-A genes. Additionally, the forced expression of miR-34a or the knockdown of MAGE-A genes by small interfering RNA similarly sensitizes medulloblastoma cells to several classes of chemotherapeutic agents, including mitomycin C and cisplatin. Finally, the analysis of mRNA and micro-RNA transcriptional profiles of a series of primary medulloblastomas identifies a subset of tumors with low miR-34a expression and correspondingly high MAGE-A expression, suggesting the coordinate regulation of these genes. Our work establishes a role for miR-34a in modulating responsiveness to chemotherapy in medulloblastoma and presents a novel positive feedback mechanism involving miR-34a and p53, via direct targeting of MAGE-A.

[1]  Z. Duan,et al.  Overexpression of MAGE/GAGE genes in paclitaxel/doxorubicin-resistant human cancer cell lines. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[2]  M. Rosner,et al.  MicroRNA-regulated feed forward loop network , 2009, Cell cycle.

[3]  C. Batt,et al.  Recombinant immunotherapeutics: current state and perspectives regarding the feasibility and market , 2010, Applied Microbiology and Biotechnology.

[4]  Daehee Hwang,et al.  Trifurcate Feed-Forward Regulation of Age-Dependent Cell Death Involving miR164 in Arabidopsis , 2009, Science.

[5]  A. Simpson,et al.  Cancer-testis (CT) antigen expression in medulloblastoma. , 2008, Cancer immunity.

[6]  William C Reinhold,et al.  MicroRNAs modulate the chemosensitivity of tumor cells , 2008, Molecular Cancer Therapeutics.

[7]  Yao-Tseng Chen,et al.  Cancer/testis antigens: an expanding family of targets for cancer immunotherapy , 2002, Immunological reviews.

[8]  P. Benedetti Panici,et al.  MAGE-A and NY-ESO-1 expression in cervical cancer: prognostic factors and effects of chemotherapy. , 2008, American journal of obstetrics and gynecology.

[9]  Jiandong Chen,et al.  MDM2 interaction with nuclear corepressor KAP1 contributes to p53 inactivation , 2005, The EMBO journal.

[10]  Ying Feng,et al.  Supplemental Data P53-mediated Activation of Mirna34 Candidate Tumor-suppressor Genes , 2022 .

[11]  Min Zhang,et al.  Restoration of tumor suppressor miR-34 inhibits human p53-mutant gastric cancer tumorspheres , 2008, BMC Cancer.

[12]  C. Croce,et al.  MicroRNA signatures in human cancers , 2006, Nature Reviews Cancer.

[13]  Carola Berking,et al.  Inactivation of miR-34a by aberrant CpG methylation in multiple types of cancer , 2008, Cell cycle.

[14]  B. Vogelstein,et al.  Infrequent p53 gene mutations in medulloblastomas. , 1991, Cancer research.

[15]  Chris Sander,et al.  Quantitative technologies establish a novel microRNA profile of chronic lymphocytic leukemia. , 2007, Blood.

[16]  Shalom Madar,et al.  p53-repressed miRNAs are involved with E2F in a feed-forward loop promoting proliferation , 2008, Molecular systems biology.

[17]  J. Rutka,et al.  Expression of MAGE and GAGE genes in medulloblastoma and modulation of resistance to chemotherapy. Laboratory investigation. , 2008, Journal of neurosurgery. Pediatrics.

[18]  Michael A. Beer,et al.  Transactivation of miR-34a by p53 broadly influences gene expression and promotes apoptosis. , 2007, Molecular cell.

[19]  M. Weller,et al.  The topoisomerase II inhibitor, genistein, induces G2/M arrest and apoptosis in human malignant glioma cell lines. , 2008, Oncology reports.

[20]  T. Poggio,et al.  Prediction of central nervous system embryonal tumour outcome based on gene expression , 2002, Nature.

[21]  Y. Taya,et al.  KAP1 dictates p53 response induced by chemotherapeutic agents via Mdm2 interaction. , 2006, Biochemical and biophysical research communications.

[22]  Yi Tie,et al.  Downregulation of CCND1 and CDK6 by miR‐34a induces cell cycle arrest , 2008, FEBS letters.

[23]  M. Yamakuchi,et al.  miR-34a repression of SIRT1 regulates apoptosis , 2008, Proceedings of the National Academy of Sciences.

[24]  A. Simpson,et al.  MAGE-A, mMage-b, and MAGE-C proteins form complexes with KAP1 and suppress p53-dependent apoptosis in MAGE-positive cell lines. , 2007, Cancer research.

[25]  J. O'Brien,et al.  Differential microRNA-34a expression and tumor suppressor function in retinoblastoma cells. , 2009, Investigative ophthalmology & visual science.

[26]  Yao-Tseng Chen,et al.  Cancer/testis (CT) antigens: Potential targets for immunotherapy , 2009, Cancer science.

[27]  H. Hermeking.  The miR-34 family in cancer and apoptosis , 2010, Cell Death and Differentiation.

[28]  R. Packer.  Childhood Brain Tumors: Accomplishments and Ongoing Challenges , 2008, Journal of child neurology.

[29]  Bernat Gel,et al.  miR-34a as a prognostic marker of relapse in surgically resected non-small-cell lung cancer. , 2009, Carcinogenesis.

[30]  Moshe Oren,et al.  Transcriptional activation of miR-34a contributes to p53-mediated apoptosis. , 2007, Molecular cell.

[31]  D. Bumcrot,et al.  MicroRNA-34 mediates AR-dependent p53-induced apoptosis in prostate cancer , 2008, Cancer biology & therapy.

[32]  N. Rajewsky,et al.  Widespread changes in protein synthesis induced by microRNAs , 2008, Nature.

[33]  T. MacDonald.  Aggressive Infantile Embryonal Tumors , 2008, Journal of child neurology.

[34]  Yitzhak Pilpel,et al.  Global and Local Architecture of the Mammalian microRNA–Transcription Factor Regulatory Network , 2007, PLoS Comput. Biol..

[35]  D. Bartel,et al.  The impact of microRNAs on protein output , 2008, Nature.

[36]  M. Pierotti,et al.  MAGE-A tumor antigens target p53 transactivation function through histone deacetylase recruitment and confer resistance to chemotherapeutic agents. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[37]  Dirk Winkler,et al.  miR-34a as part of the resistance network in chronic lymphocytic leukemia. , 2008, Blood.

[38]  Yasunori Fujita,et al.  Effects of miR-34a on cell growth and chemoresistance in prostate cancer PC3 cells. , 2008, Biochemical and biophysical research communications.

[39]  C. Bokemeyer,et al.  Cell-cycle progression and response of germ cell tumors to cisplatin in vitro. , 2006, International journal of oncology.

[40]  S. Pomeroy,et al.  Targeted Therapy in Medulloblastoma in Molecularly Targeted Therapy for Childhood Cancer , 2010 .

[41]  Sharon J. Diskin,et al.  A Functional Screen Identifies miR-34a as a Candidate Neuroblastoma Tumor Suppressor Gene , 2008, Molecular Cancer Research.

[42]  K. Smalley,et al.  Farnesyl transferase inhibitor SCH66336 is cytostatic, pro‐apoptotic and enhances chemosensitivity to cisplatin in melanoma cells , 2003, International journal of cancer.

[43]  G. Gronowicz,et al.  miR-29 Modulates Wnt Signaling in Human Osteoblasts through a Positive Feedback Loop* , 2010, The Journal of Biological Chemistry.

[44]  M. Cusick,et al.  Plasma membrane calcium pumps in mouse olfactory sensory neurons. , 2006, Chemical senses.

[45]  JiangXiao,et al.  Biological functions of melanoma-associated antigens , 2004 .

[46]  J. Rader,et al.  Oncogenic HPV infection interrupts the expression of tumor-suppressive miR-34a through viral oncoprotein E6. , 2009, RNA.

[47]  P. Coulie,et al.  Cytolytic T‐cell responses of cancer patients vaccinated with a MAGE antigen , 2002 .

[48]  J Khan,et al.  The MYCN oncogene is a direct target of miR-34a , 2008, Oncogene.

[49]  M. Yamakuchi,et al.  MiR-34, SIRT1, and p53: The feedback loop , 2009, Cell cycle.

[50]  Yuval Kluger,et al.  Inter- and intra-combinatorial regulation by transcription factors and microRNAs , 2007, BMC Genomics.

[51]  A. Giordano,et al.  Medulloblastoma: From Molecular Pathology to Therapy , 2008, Clinical Cancer Research.

[52]  Naoto Tsuchiya,et al.  Tumor-suppressive miR-34a induces senescence-like growth arrest through modulation of the E2F pathway in human colon cancer cells , 2007, Proceedings of the National Academy of Sciences.

[53]  G. Demers,et al.  Loss of normal p53 function confers sensitization to Taxol by increasing G2/M arrest and apoptosis , 1996, Nature Medicine.

[54]  R. Stallings,et al.  MicroRNA-34a functions as a potential tumor suppressor by inducing apoptosis in neuroblastoma cells , 2007, Oncogene.

[55]  Kazuhiro Yoshida,et al.  Melanoma-associated antigen-A1 expression predicts resistance to docetaxel and paclitaxel in advanced and recurrent gastric cancer. , 2007, Oncology reports.

[56]  A. Farcomeni,et al.  MicroRNA profiling in human medulloblastoma , 2009, International journal of cancer.